Treatment of Myocardial Infarction and Vascular Injury with Netrin-1
AssigneeThe Regents of the University of California
InventorHua Cai
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Regents of the University of California
InventorHua Cai
Estimating the term…
Disclosed herein are methods for treating, inhibiting, or reducing ischemia/reperfusion injury of a cardiac tissue; increasing phosphorylation of ERK1/2 and/or eNOS in a cardiac tissue; treating, inhibiting, or reducing loss of NO; treating, inhibiting, or reducing uncoupling of NOS; increasing recoupling of NOS; treating, inhibiting, or reducing loss of DCC protein and mRNA expression in a cardiac tissue; decreasing or reducing the infarct size of a heart resulting from ischemia/reperfusion injury; decreasing or reducing superoxide production by a cardiac tissue caused by ischemia/reperfusion injury; treating, inhibiting, or reducing neointimal formation and restenosis; treating, inhibiting, or reducing apoptosis of mobilized endothelial progenitor cells; or a combination thereof of a blood vessel (such as an artery, a coronary artery, a vein, or a capillary) or a portion of the blood vessel in a subject which comprise the administration of netrin-1.
A method of decreasing or reducing the infarct size of a heart resulting from ischemia/reperfusion injury which comprises
2-26. (canceled)
A method of treating, inhibiting or reducing a disease or a condition in a cardiac tissue, a heart, a blood vessel, an endothelial progenitor cell, or a vascular smooth muscle cell, which comprises
A method of treating endothelial progenitor cells to reduce apoptosis resulting from exposure to oxidative stress or improve the quality of the endothelial progenitor cells prior to use in a cell-based therapy which comprises
Dependencies are inferred from the claim text.